目的 探討復(fù)方玄駒膠囊聯(lián)合左氧氟沙星和前列康片治療Ⅲ型前列腺炎的臨床療效.方法 選取2012 年1 月-2015年1 月北京市通州區(qū)新華醫(yī)院收治的Ⅲ型前列腺炎患者156 例,隨機(jī)分為對照組和治療組,每組78 例.對照組口服左氧氟沙星片5 片/次,1 次/d,口服前列康片3 片/次,3 次/d.治療組在對照組基礎(chǔ)上口服復(fù)方玄駒膠囊3 粒/次,3 次/d.兩組均連續(xù)治療6 周.觀察兩組的臨床療效,同時比較兩組NIH-CPSI 評分和前列腺液檢查的變化情況.結(jié)果 治療后,對照組和治療組總有效率分別為51.28%、71.79%,兩組比較差異具有統(tǒng)計學(xué)意義(P< 0.05).治療后兩組NIH-CPSI 總分、疼痛、排尿、生活質(zhì)量得分均較治療前顯著降低,同組治療前后差異有統(tǒng)計學(xué)意義(P< 0.05),且治療組顯著低于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P< 0.05).治療后,兩組精液中白細(xì)胞介素-6(IL-6)、白細(xì)胞水平均顯著降低,同組治療前后差異有統(tǒng)計學(xué)意義(P< 0.05),且治療組顯著低于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P< 0.05).結(jié)論 復(fù)方玄駒膠囊聯(lián)合左氧氟沙星和前列康片治療Ⅲ型前列腺炎療效顯著,可顯著降低NIH-CPSI 評分,具有一定的臨床推廣應(yīng)用價值.

Objective To investigate the curative effect of Compound Xuanju Capsule combined with levofloxacin and Qianliekang Tablets in treatment of type Ⅲ prostatitis. Methods Patients (156 cases) with type Ⅲ prostatitis in Beijing Tongzhou Xinhua Hospital from January 2012 to January 2015 were randomly divided into control and treatment groups. Each group had 78 cases. Patients in control group were po administered with Levofloxacin Tablets, 5 tablets/time, once daily, and they were po administered with Qianliekang Tablets, 3 tablets/time, three times daily. Patients in treatment group were po administered with Compound Xuanju Capsule on the basis of the control group, 3 grains/time, three times daily. Two groups were treated for 6 weeks. After treatment, the efficacy was evaluated, and NIH-CPSI score and examination of prostatic fluid in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 51.28% and 71.79%, respectively, and there were differences between two groups (P < 0.05). After treatment, NIH-CPSI total score, scores of pain, micturition, and life quality in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment were significantly lower than those in the control group, with significant differences between two groups (P < 0.05). After treatment, IL-6 and white blood cell in the semen of two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment were significantly lower than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Compound Xuanju Capsule combined with levofloxacin and Qianliekang Tablets has curative effec in treatment of type Ⅲ prostatitis, and can significantly reduce the NIH-CPSI score, which has a certain clinical application value.